Nasus Pharma Ltd.
- NSRX · NYSE
- Pharmaceutical Preparations
- Tel Aviv - Yafo, L3
- CIK 0002029039
Updated from SEC filings through
Top things to know
Executives
- Brendan P. O'Grady Chief Executive Officer Form 3, July 31, 2026
- Dan Benjamin Teleman Chief Executive Officer Form 4, July 29, 2026
- Nir Sassi Chief Financial Officer Form 3, November 19, 2026
- Oren Elmaliah Interim CFO Form 3, September 23, 2026
- Eyal Rubin Chief Financial Officer Form 4, September 21, 2026
- Dalia Megiddo Chief Development Officer Form 3, March 27, 2026
Nasus Pharma Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Tel Aviv - Yafo, L3. It trades as NSRX on NYSE. Revenue was $1.2B in the fiscal year ending December 31, 2025. Brendan P. O'Grady is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.2B 20-F, 2026-03-25 | Not on file | Not on file |
| Operating income | -$4.9M 20-F, 2026-03-25 | -$1.1M 20-F, 2026-03-25 | -$1.1M 20-F, 2026-03-25 |
| SG&A | $2.7M 20-F, 2026-03-25 | $743K 20-F, 2026-03-25 | $580K 20-F, 2026-03-25 |
| Net income | -$5.9M 20-F, 2026-03-25 | -$1.5M 20-F, 2026-03-25 | -$1.1M 20-F, 2026-03-25 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Brendan P. O'Grady | Chief Executive Officer | Form 3, July 31, 2026 |
| Dan Benjamin Teleman | Chief Executive Officer | Form 4, July 29, 2026 |
| Nir Sassi | Chief Financial Officer | Form 3, November 19, 2026 |
| Oren Elmaliah | Interim CFO | Form 3, September 23, 2026 |
| Eyal Rubin Global CFO | Strategic Finance, M&A & Capital Markets | Driving Growth, Governance & Operational Excellence | Pharma · Biotech · Tech | Chief Financial Officer | Form 4, September 21, 2026 |
| Dalia Megiddo | Chief Development Officer | Form 3, March 27, 2026 |
What Nasus Pharma Ltd does
Nasus Pharma develops powder-based intranasal therapies using Nasax® technology for rapid drug delivery, improved absorption, and emergency treatments.
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Shares outstanding | 9.0 million (as of December 31, 2025) | 20-F, March 25, 2026 |
|---|---|---|
| Auditor | Brightman Almagor Zohar & Co (Tel -Aviv, Israel) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| June 17, 2026 | Dan Benjamin Teleman Chief Executive Officer | Buy | 6,550 | $20K | Form 4, June 22, 2026 |
| April 22, 2026 | Dan Benjamin Teleman Chief Executive Officer | Buy | 2,900 | $11K | Form 4, April 22, 2026 |
| March 31, 2026 | Dan Benjamin Teleman Chief Executive Officer | Buy | 15,000 | $31K | Form 4, April 1, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Nasus Pharma Ltd
- What does Nasus Pharma Ltd do?
- In its own words, from Item 1 of its 10-K: "Nasus Pharma develops powder-based intranasal therapies using Nasax® technology for rapid drug delivery, improved absorption, and emergency treatments."
- What is Nasus Pharma Ltd's revenue?
- $1.2B for the fiscal year ending December 31, 2025, from its 20-F filed March 25, 2026.
- Is Nasus Pharma Ltd profitable?
- Nasus Pharma Ltd reported net income of -$5.9M for the fiscal year ending December 31, 2025.
- Who is the CEO of Nasus Pharma Ltd?
- Brendan P. O'Grady, Chief Executive Officer, as named in a 3 filed July 31, 2026.
- Who is the CFO of Nasus Pharma Ltd?
- Nir Sassi, Chief Financial Officer, as named in a 3 filed November 19, 2026.
- Where is Nasus Pharma Ltd headquartered?
- Tel Aviv - Yafo, L3.
- What is Nasus Pharma Ltd's stock ticker?
- NSRX on NYSE.
- What industry is Nasus Pharma Ltd in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Nasus Pharma Ltd's website?
- nasuspharma.com. Investor relations: https://ir.nasuspharma.com/.
- Is Nasus Pharma Ltd a public company?
- Yes. Nasus Pharma Ltd files with the SEC under CIK 0002029039 and trades as NSRX.
- Who audits Nasus Pharma Ltd?
- Brightman Almagor Zohar & Co, Tel -Aviv, Israel, as named in its latest annual report (10-K).
- How many shares of Nasus Pharma Ltd are outstanding?
- 9.0 million shares as of December 31, 2025, from its 20-F filed March 25, 2026.
- Have Nasus Pharma Ltd insiders traded stock recently?
- Since March 31, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $62K on Forms 4 and 5. The most recent: Dan Benjamin Teleman (Chief Executive Officer) bought 6,550 shares on June 17, 2026.